Regeneron Pharmaceuticals Statistics

Total Valuation

Regeneron Pharmaceuticals has a market cap or net worth of GBP 60.06 billion. The enterprise value is 47.67 billion.

Market Cap	60.06B
Enterprise Value	47.67B

Important Dates

The next estimated earnings date is Monday, February 3, 2025.

Earnings Date	Feb 3, 2025
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	n/a
Shares Outstanding	n/a
Shares Change (YoY)	+1.16%
Shares Change (QoQ)	+0.69%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	103.10M

Valuation Ratios

The trailing PE ratio is 17.30.

PE Ratio	17.30
Forward PE	n/a
PS Ratio	n/a
PB Ratio	n/a
P/TBV Ratio	2.85
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 12.98, with an EV/FCF ratio of 18.57.

EV / Earnings	13.73
EV / Sales	4.33
EV / EBITDA	12.98
EV / EBIT	14.52
EV / FCF	18.57

Financial Position

The company has a current ratio of 5.28, with a Debt / Equity ratio of 0.09.

Current Ratio	5.28
Quick Ratio	4.34
Debt / Equity	0.09
Debt / EBITDA	0.59
Debt / FCF	0.79
Interest Coverage	65.53

Financial Efficiency

Return on equity (ROE) is 17.17% and return on invested capital (ROIC) is 8.65%.

Return on Equity (ROE)	17.17%
Return on Assets (ROA)	7.41%
Return on Capital (ROIC)	8.65%
Revenue Per Employee	729,356
Profits Per Employee	245,162
Employee Count	13,450
Asset Turnover	0.40
Inventory Turnover	2.44

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -17.29% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	-17.29%
50-Day Moving Average	821.56
200-Day Moving Average	980.49
Relative Strength Index (RSI)	25.92
Average Volume (20 Days)	1,523

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	2.12

Income Statement

In the last 12 months, Regeneron Pharmaceuticals had revenue of GBP 10.33 billion and earned 3.47 billion in profits. Earnings per share was 30.16.

Revenue	10.33B
Gross Profit	5.24B
Operating Income	3.08B
Pretax Income	3.71B
Net Income	3.47B
EBITDA	3.43B
EBIT	3.08B
Earnings Per Share (EPS)	30.16

Full Income Statement

Balance Sheet

The company has 7.31 billion in cash and 2.02 billion in debt, giving a net cash position of 11.63 billion.

Cash & Cash Equivalents	7.31B
Total Debt	2.02B
Net Cash	11.63B
Net Cash Per Share	n/a
Equity (Book Value)	21.88B
Book Value Per Share	202.97
Working Capital	11.69B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 3.17 billion and capital expenditures -602.62 million, giving a free cash flow of 2.57 billion.

Operating Cash Flow	3.17B
Capital Expenditures	-602.62M
Free Cash Flow	2.57B
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross margin is 50.75%, with operating and profit margins of 29.81% and 33.61%.

Gross Margin	50.75%
Operating Margin	29.81%
Pretax Margin	35.89%
Profit Margin	33.61%
EBITDA Margin	33.21%
EBIT Margin	29.81%
FCF Margin	24.84%

Dividends & Yields

Regeneron Pharmaceuticals does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-1.16%
Shareholder Yield	-1.16%
Earnings Yield	5.33%
FCF Yield	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Regeneron Pharmaceuticals has an Altman Z-Score of 10.04.

Altman Z-Score	10.04
Piotroski F-Score	n/a